Caixin
Caixin Global – Latest China News & Headlines

Home >

ABOUT US

CX Live is Caixin Global's real-time news portal, featuring 24-hour breaking news, short-form analysis, and roundups from business and social media in China.

TRENDING
China Launches EV Safety Inspection After Tesla and Nio Fires
Bank of East Asia to Increase Mainland Capital After Profit Warning
TikTok Owner ByteDance Hits 1 Billion Users
LATEST
Suzhou HYC to Start Subscription for New-Board IPO June 27
Head of Hebei Government Newspaper Under Investigation
Tencent Reshuffles Leadership of Fintech Business
Local Government Crackdowns on Some ‘Foreign’ or ‘Feudal’ Place Names Draws Debate
Chinese E-Commerce Players Boast Record Sales During Mid-Year Shopping Festival
'Three-Body Problem' TV Series in the Works
Xiaomi to Invest 5 Billion Yuan in Retail Channels
TikTok Owner ByteDance Hits 1 Billion Users
PBOC Again Moves Against Yuan Shorters With Hong Kong Bill Issuance
Growing Parade of China Tech ‘Losers’ Line Up for New York Listings
China's Got More Competition Now as Info-Tech Exporter to the U.S.
Xpeng Makes 10,000th Car Amid Plans for New Fundraising Round
Debt-Saddled China Railway Restructures in Line With State Sector Reform Push
Company Dismisses Own Swine Fever Vaccine Claim as ‘Typo’
Warning System Gives Heads-Up on Monday’s Deadly Sichuan Earthquake
Alibaba Makes Major Changes to Culture and Entertainment Unit Amid IPO Rumors
Illicit Drugs From Overseas on Rise, China Says
Taiwan's TPK Withdraws From Bailout of Troubled Japanese Apple Screen Supplier
Sichuan Earthquake Death Toll Rises to 12
Google Appoints New Chief to Oversee China Region
Chinese DNA Sequencing Firm BGI Faces Legal Battle with Illumina

By Wang Luyao and Han Wei / May 24, 2019 02:59 AM / Business & Tech

Photo: VCG

Photo: VCG

Chinese genomics giant BGI Group said it is prepared in the face of rising legal disputes in Europe and may resort to counterclaims to fight patent infringement allegations.

BGI is “actively responding to recent patent disputes and will take corresponding legal actions,” BGI said in a statement to Caixin Thursday, adding that it “will not rule out the use of legal weapons such as counterclaims to protect its legal rights.”

BGI’s subsidiary BGI Europe was sued by Illumina Inc. in Denmark on alleged patent infringement last week. The complaint alleged BGI's sequencing products and related sequencing chemistry reagents infringe on Illumina's European patent.

The case followed another infringement suit filed by Illumina in Germany against another BGI subsidiary, Latvia MGI Tech, in March.

In the statement, BGI said it is confident in its own technology, which cost billions of yuan to develop and “broke the market monopoly in the upstream genome sequencing market.”

When interviewed by Caixin earlier this month on whether Illumina will file more suits against BGI outside Europe, the company’s Chief Commercial Officer Mark Van Oene said Illumina will continue pursuing patent protection, without elaborating.

Established in 1999, BGI was a client of Illumina’s sequencing equipment but has started to develop its own devices after purchasing U.S. genomics company Complete Genomics in 2012.

Related: BGI Genomics’ Profits Slip As Questions Linger About Its Services


Share this article
Open WeChat and scan the QR code
Copyright © 2019 Caixin Global Limited. All Rights Reserved.